Canget BioTekpharma Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Angel
  • (Cancelled)
  • Investors
  • 2

Canget BioTekpharma General Information

Description

Operaator of a biotechnology company intended to develop novel, cancer-targeting anticancer agents. The company provides highly effective, low toxic and cancer-targeting anticancer agents for patients, enabling medical practitioners to dramatically improve patient survival time and survival rate through controlling cancer cell drug resistance and tumor relapse.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Primary Office
  • 701 Ellicott Street
  • Buffalo, NY 14203
  • United States
+1 (716) 000-0000

Canget BioTekpharma Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Canget BioTekpharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Angel (individual) 01-Feb-2020 Cancelled Pre-Clinical Trials
6. Angel (individual) 29-Feb-2020 00000 00000 Completed Pre-Clinical Trials
5. Angel (individual) 03-Jul-2019 00000 00000 Completed Generating Revenue
4. Grant 01-Jan-2018 00000 Completed Startup
3. Grant 01-Jan-2015 00.00 Completed Startup
2. Grant 01-Jan-2014 $225K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Canget BioTekpharma’s complete valuation and funding history, request access »

Canget BioTekpharma Patents

Canget BioTekpharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3111403-A1 Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease Pending 17-Sep-2018 0000000000
EP-3852760-A2 Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease Pending 17-Sep-2018 0000000000
US-20200231596-A1 Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease Pending 17-Sep-2018 C07D491/22

Canget BioTekpharma Executive Team (5)

Name Title Board Seat Contact Info
John Seman Ph.D Chief Executive Officer & Board Member
Fengzhi Li Ph.D Founder, Chief Scientific Officer & Advisor
Scott Friedman ESQ General Counsel & Manager
Alex Adjei Chief Medical Officer & Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

Canget BioTekpharma Board Members (1)

Name Representing Role Since
John Seman Ph.D Canget BioTekpharma Chief Executive Officer & Board Member 000 0000
To view Canget BioTekpharma’s complete board members history, request access »

Canget BioTekpharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Canget BioTekpharma Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
Start-up NY Accelerator/Incubator Minority 000 0000 000000 0
To view Canget BioTekpharma’s complete investors history, request access »